{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:42:56Z","timestamp":1776231776178,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-muscle invasive bladder cancer (NMIBC) is characterized by frequent recurrence, requiring repeated cystoscopic surveillance that is invasive and burdensome for patients. Although liquid biopsy approaches have been explored, clinically applicable non-invasive biomarkers that directly reflect tumor burden remain limited. As a proof-of-concept, we investigated whether somatic mutant proteins derived from bladder cancer cells can be detected and quantified in urinary extracellular vesicles (EVs) using a proteogenomic strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor tissues, cultured tissue-derived EVs, and urinary EVs were collected from five patients with bladder cancer. Whole-exome sequencing was performed to generate patient-specific mutation databases. Deep proteomic profiling by LC\/MS was conducted for each specimen type, followed by a proteogenomic pipeline to identify somatic mutant proteins. To explore clinical feasibility, selected mutant proteins were further evaluated by targeted mass spectrometry with absolute quantification in prospectively collected urine samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comprehensive proteomic analyses identified 11, 207 proteins in tumor tissues, 9, 809 in tissue-derived EVs, and 5, 828 in urinary EVs. Across these matched sample sets, 39, 32, and 4 somatic mutant proteins were detected, respectively, demonstrating that tumor-specific mutant proteins are incorporated into EVs and released into urine. Importantly, absolute quantification of selected mutant proteins (LCP1_D321H, TKT_K102N, and PLCD1_R639H) revealed a clear association between urinary EV mutant protein levels and cystoscopic tumor burden, supporting their potential utility for non-invasive disease monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This proof-of-concept study provides the first evidence that somatic mutant proteins can be directly detected and quantified in urinary EVs using a proteogenomic approach. Our findings establish a conceptual framework for mutation-informed, protein-level liquid biopsy and suggest that urinary EV-associated mutant proteins may serve as highly specific, non-invasive biomarkers for monitoring bladder cancer recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1808671","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:43:25Z","timestamp":1776228205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteogenomic detection of tumor-specific somatic mutant proteins in urinary extracellular vesicles for non-invasive monitoring of bladder cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuji","family":"Hakozaki","sequence":"first","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]},{"name":"Department of Urology, The University of Tokyo Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]},{"name":"Department of Urology, The University of Tokyo Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Danno","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shinchi","sequence":"additional","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Tokyo Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ueda","sequence":"additional","affiliation":[{"name":"Division of Analytical Biochemistry, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3577","article-title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA","volume":"29","author":"Matsubara","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","article-title":"Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study","volume":"7","author":"Forschner","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657483","article-title":"Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101726","article-title":"Phenotypic switching of na\u00efve T cells to immune-suppressive Treg-like cells by mutant KRAS","volume":"8","author":"Kalvala","year":"2019","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1725","article-title":"Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells","volume":"10","author":"Al-Nedawi","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M112.022806","article-title":"Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS","volume":"12","author":"Demory Beckler","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa616","article-title":"Neoantimon: a multifunctional R package for identification of tumor-specific neoantigens","volume":"36","author":"Hasegawa","year":"2020","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.9b00640","article-title":"Skyline for small molecules: A unifying software package for quantitative metabolomics","volume":"19","author":"Adams","year":"2020","journal-title":"J Proteome Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3144","article-title":"Proteogenomics: concepts, applications and computational strategies","volume":"11","author":"Nesvizhskii","year":"2014","journal-title":"Nat Methods"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-014-0064-y","article-title":"FLAGS, frequently mutated genes in public exomes","volume":"7","author":"Shyr","year":"2014","journal-title":"BMC Med Genomics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105416","article-title":"Urinary extracellular vesicles signature for diagnosis of kidney disease","volume":"25","author":"Takizawa","year":"2022","journal-title":"iScience"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14881","article-title":"Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers","volume":"112","author":"Tomiyama","year":"2021","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/srep33935","article-title":"A novel affinity-based method for the isolation of highly purified extracellular vesicles","volume":"6","author":"Nakai","year":"2016","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2021.100138","article-title":"Trapped ion mobility spectrometry and parallel accumulation-serial fragmentation in proteomics","volume":"20","author":"Meier","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx405","article-title":"Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance","volume":"28","author":"Barata","year":"2017","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100273","article-title":"Quantitative proteomics identifies proteins enriched in large and small extracellular vesicles","volume":"21","author":"Lischnig","year":"2022","journal-title":"Mol Cell Proteomics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1041327","article-title":"Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis","volume":"13","author":"Tepus","year":"2022","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1038\/s41467-024-49424-5","article-title":"Prostate cancer reshapes the secreted and extracellular vesicle urinary proteomes","volume":"15","author":"Khoo","year":"2024","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1038\/s41467-018-07339-y","article-title":"Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels","volume":"9","author":"Novo","year":"2018","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717527","article-title":"Association analyses of TP53 mutation with prognosis, tumor mutational burden, and immunological features in acute myeloid leukemia","volume":"12","author":"Wen","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.05.003","article-title":"Single extracellular vesicle analysis for early cancer detection","volume":"28","author":"Ferguson","year":"2022","journal-title":"Trends Mol Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer - current status and future perspectives","volume":"20","author":"Maas","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/s0090-4295(98)00219-2","article-title":"Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer","volume":"52","author":"Landman","year":"1998","journal-title":"Urology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21327","article-title":"Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation","volume":"121","author":"Dimashkieh","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jmoldx.2022.10.004","article-title":"A micro-costing framework for circulating tumor DNA testing in Dutch clinical practice","volume":"25","author":"Kramer","year":"2023","journal-title":"J Mol Diagn"},{"key":"B36","unstructured":"UltraSEEK Lung Panel"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jex2.70035","article-title":"Comparison of methods for isolation and characterization of total and astrocyte-enriched extracellular vesicles from human serum and plasma","volume":"4","author":"Figueroa-Hall","year":"2025","journal-title":"J Extracell Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.2c00265","article-title":"In search of a universal method: A comparative survey of bottom-up proteomics sample preparation methods","volume":"21","author":"Varnavides","year":"2022","journal-title":"J Proteome Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010084","article-title":"A comprehensive assessment of genetic and epigenetic alterations identifies frequent variations impacting six prototypic SCF complex members","volume":"23","author":"Campos Gudi\u00f1o","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808671\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:43:33Z","timestamp":1776228213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808671\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":39,"alternative-id":["10.3389\/fonc.2026.1808671"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1808671","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1808671"}}